Furthermore, subgroup analysis of the Sarculator nomogram-predicted worst prognostic group demonstrated a nonsignificant trend toward improved disease-free survival and OS in patients receiving anthracycline-based neoadjuvant chemotherapy 15 .
1
—
—
Furthermore, subgroup analysis of the Sarculator nomogram-predicted worst prognostic group demonstrated a nonsignificant trend toward improved disease-free survival and OS in patients receiving anthracycline-based neoadjuvant chemotherapy 15 .